Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Diagnostics Cancer Clinical Trials

Minute Insight: Mainz Biomed Shows Off New Colorectal Cancer Diagnostic Test Data

  • News

Executive Summary

The company’s ColoAlert mRNA-based diagnostic has proven similarly efficacious to colonoscopy, while outperforming competing blood/stool-based diagnostics.

You may also be interested in...



Exact Sciences Nails Colorectal Cancer Test Trial Ahead Of Planned Submission

Exact Sciences’ next generation of Cologuard, which could be on the market later this year, clearly outperforms its previous.

Minute Insight: Maestro Cues The Music With CE Mark For Moon Surgical

The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.

Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Table

View full table

Topics

Tags:
Diagnostics Cancer Clinical Trials
Latest Headlines

Minute Insight: Maestro Cues The Music With CE Mark For Moon Surgical

Boston Scientific Puts Charge In Neuromodulation Business By Acquiring Relievant

Optimizing EU Medtech Regulatory Governance And Innovation: First Workshop Shapes Future Study

Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical

See All
UsernamePublicRestriction

Register

MT148259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By